MMF versus TAC in pediatric SSNS with FRNS and SDNS
IgA and steroids: the saga continues
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.
— Nephrology Journal Club (@NephJC) January 20, 2023
Up first is NefIgArd.
We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?
IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP